摘要
目的 :探索血管生长素 (angiogenin,ANG)对缺血性心肌的促血管生长作用 ,以评价其应用于生物治疗的可行性。方法 :以先期成功表达的基因重组人血管生长素衍生物 Asp116 His对心肌梗死模型兔的缺血心肌边缘部作直接心肌内注射。注射后 8d行冠状动脉血管造影 ,并取注射点心肌切片作常规病理苏木精 -伊红染色、VB染色、 因子相关抗原免疫组化标记。结果 :用药组兔心脏表面注射点周围心肌缺血情况较对照组明显减轻 ,镜检可见心肌间质内有大量小血管 ,免疫组化标记发现心肌纤维间毛细血管数明显增多。结论 :首次证实了 ANG在心脏冠状血管内存在有效作用位点 ;ANG有可能成为缺血心肌再血管化生物治疗因子。
Objective: To investigate the angiogenic potentiality of angiogenin in ischemic myocardium and estimate the possibility of its application in biologic treatment. Methods: Recombinant human angiogenin derivative Asp116His was applied in an acute myocardial infarction model in rabbits which were established by direct intramyocardial injection into the border zone of the ischemic myocardium. The animals were sacrificed on the eighth postoperative day and their hearts were harvested and subjected to histologic studies. Results: Myocardium around the injection sites was apparently less ischemia in the experiment group as compared with control groups. A large number of small vessels were observed in the interstitial tissues and even more were revealed in the myocardium on immunohistochemistry studies. Conclusion: The results indicate for the first time that angiogenin or its derivatives may act on ischemic myocardium and stimulate neo angiogenesis, which holds great promise for their future application in biologic revascularization of ischemic myocardium.
出处
《第二军医大学学报》
CAS
CSCD
北大核心
2000年第3期216-218,F003,共4页
Academic Journal of Second Military Medical University
基金
国家自然科学基金!( 3 9970 73 5 )
